Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 5, 2005, Pages 1474-1482

  Vargas, Carlos Enrique ^a   Galalae, Razavan ^b   Demanes, Jeffrey ^c   Harsolia, Asif ^a   Meldolesi, Elisa ^a   Nürnberg, Nils ^d   Schour, Lionel ^c   Martinez, Alvaro ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c California Endocuritherapy Cancer Center   (United States)

^d Stadtisches Krankenhaus Kiel   (Germany)

Author keywords

High dose rate brachytherapy; Pelvic radiation; Prostate cancer; Radiation therapy

Indexed keywords

ANTIGENS; BIOCHEMISTRY; DISEASES; DOSIMETRY; RADIOTHERAPY; TUMORS;

HIGH-DOSE-RATE BRACHYTHERAPY; LYMPH NODES (LN); PELVIC RADIATION; PROSTATE CANCER;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RISK BENEFIT ANALYSIS; SEMINAL VESICLE; STATISTICAL ANALYSIS; THEORETICAL MODEL; TREATMENT PLANNING;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; HUMANS; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RELATIVE BIOLOGICAL EFFECTIVENESS; RISK FACTORS;

EID: 27744518816     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.04.026     Document Type: Article

References (27)

1. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) A phase III randomised trial Lancet 360 2002 103 106
2. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. DellaCroce, P.W. Kantoff 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer A randomized controlled trial JAMA 292 2004 821 827
3. G.E. Hanks, T.F. Pajak, A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
4. A. Martinez, J. Gonzalez, W. Spencer Conformal high-dose-rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors J Urol 169 2003 974 979
5. M.V. Pilepich, K. Winter, M.J. John Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
6. M.V. Pilepich, K. Winter, C. Lawton Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate Long-term results of phase III RTOG study 85-31 [Abstract] Int J Radiat Oncol Biol Phys 57 2003 s172
7. M. Roach III, M. DeSilvio, C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
8. F.A. Vicini, C. Vargas, G. Edmundson, L. Kestin, A. Martinez The role of high-dose rate brachytherapy in locally advanced prostate cancer Semin Radiat Oncol 13 2003 98 108
9. S.O. Asbell, J.M. Krall, M.V. Pilepich Elective pelvic irradiation in stage A2, B carcinoma of the prostate Analysis of RTOG 77-06 Int J Radiat Oncol Biol Phys 15 1988 1307 1316
10. A. Pollack, G.K. Zagars, G. Starkschall Prostate cancer radiation dose response Results of the M.D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
11. D.J. Demanes, R.R. Rodriguez, G.A. Altieri High-dose-rate prostate brachytherapy The California Endocurietherapy (CET) method Radiother Oncol 57 2000 289 296
12. R.M. Galalae, A. Martinez, T. Mate Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer Int J Radiat Oncol Biol Phys 58 2004 1048 1055
13. M. Roach III, C. Marquez, H.S. Yuo Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 28 1994 33 37
14. American Joint Committee on Cancer Prostate O.H. Beahrs D.E. Henson R.V.P. Hutter B.J. Kennedy AJCC cancer staging manual 4th ed 1992 Lippincott-Raven Philadelphia 181 186
15. D.J. Brenner, A.A. Martinez, G.K. Edmundson, C. Mitchell, H.D. Thames, E.P. Armour Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
16. Agency for Health Care Policy and Research. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostatic Cancer. http://www.ahrq.gov/clinic/epcsums/prossumm.htm 1999. Accessed on July 14, 2004.
17. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
18. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
19. D.R. Cox Regression models and life-tables J R Stat Soc B 34 1972 187 220
20. A. Martinez, C. Vargas, J. Demanes Detrimental outcomes of short term hormonal treatment and high dose radiation therapy (EBRT plus HDR) when compared with EBRT plus HDR alone for high-risk prostate patients [Abstract] Int J Radiat Oncol Biol Phys 60 Suppl. 1 2004 S469
21. J. Crook, C. Ludgate, S. Malone Report of a multicenter Canadian Phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 60 2004 15 23
22. A.W. Partin, J. Yoo, H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114
23. A.W. Partin, L.A. Mangold, D.M. Lamm, P.C. Walsh, J.I. Epstein, J.D. Pearson Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium Urology 58 2001 843 848
24. D. Fitch, L. Kestin, C. Vargas, A. Martinez, F.A. Vicini Unification of a common biochemical failure definition across multiple treatment modalities [Abstract] Int J Radiat Oncol Biol Phys 60 Suppl. 1 2004 S171 S172
25. H.M. Sandler, T.F. Pajak, G.E. Hanks, A. Porter, M. DeSilvio, W. Shipley Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Analysis of RTOG Protocol 92-02 [Abstract] Proc Am Soc Clin Oncol 22 2004 381
26. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
27. R. Jacob, A.L. Hanlon, E.M. Horwitz, B. Movsas, R.G. Uzzo, A. Pollack Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement Int J Radiat Oncol Biol Phys 61 2005 695 701